Clearmind Medicine Closes US$2.25 Million Public Offering
18 Septiembre 2023 - 11:16AM
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY)
(“Clearmind”), a biotech company focused on the discovery and
development of novel psychedelic-derived therapeutics to solve
major under-treated health problems, today announced the closing of
its United States only public offering made on a reasonable best
efforts basis with gross proceeds to the Company of approximately
US$2.25 million, before deducting placement agent fees and other
expenses payable by the Company. The offering consisted of
7,500,000 common shares and pre-funded warrants and 7,500,000
common warrants. The common warrants are immediately exercisable,
will expire five years from the date of issuance and will have an
exercise price of US$0.30 (CAD$0.40) per common share. Each
common share (or pre-funded warrant in lieu thereof) was sold
together with one common warrant at a combined purchase price of
US$0.30 (CAD$0.40) per share (or US$0.299 (CAD$0.399) per
pre-funded warrant after reducing US$0.001 (CAD$0.001)
attributable to the exercise price of the pre-funded warrants) but
were issued separately. The common warrants and pre-funded warrants
are not listed on any exchange.
The Company expects to use the net proceeds from the offering,
for general corporate purposes, which may include operating
expenses, research and development, including clinical and
pre-clinical testing of its product candidates, working capital,
future acquisitions and general capital expenditures.
The offering was not made in Canada and residents of Canada
did not purchase any securities in the offering.
Aegis Capital Corp. acted as exclusive placement agent
for the offering.
A registration statement on Form F-1 (File No. 333-273293)
relating to the offering of the securities was filed with the U.S.
Securities and Exchange Commission (SEC) and declared effective by
the SEC on September 14, 2023. The offering was made only by means
of a prospectus. A final prospectus describing the terms of the
proposed transaction is available, on the SEC's website,
www.sec.gov or by contacting Aegis Capital Corp., 1345 Avenue
of the Americas, 27th Floor, New York, NY 10105, by telephone at
(212) 813-1010 or by email at syndicate@aegiscap.com. This press
release shall not constitute an offer to sell or a solicitation of
an offer to buy, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company
focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently consists of
fourteen patent families. The Company intends to seek additional
patents for its compounds whenever warranted and will remain
opportunistic regarding the acquisition of additional intellectual
property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the
Canadian Securities Exchange under the symbol "CMND" and the
Frankfurt Stock Exchange under the symbol “CWY.”
For further information visit:
https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. Forward-looking statements are not
historical facts, and are based upon management’s current
expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no
assurance that management’s expectations, beliefs and projections
will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking
statements. In addition, we cannot assure that any patent will
issue as a result of a pending patent application or, if issued,
whether it will issue in a form that will be advantageous to us.
Forward-looking statements are subject to risks and uncertainties
that could cause actual performance or results to differ materially
from those expressed in the forward-looking statements. For a more
detailed description of the risks and uncertainties affecting the
Company, reference is made to the Company’s reports filed from time
to time with the Securities and Exchange Commission (“SEC”),
including, but not limited to, the risks detailed in the Company’s
annual report on Form 20-F filed with the SEC on February 6, 2023
and the Company's preliminary prospectus (Registration No.
333-273293), filed with the SEC on September 13, 2023.
Forward-looking statements speak only as of the date the statements
are made. The Company assumes no obligation to update
forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other
factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update
one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect
thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not
responsible for the contents of third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Clearmind Medicine (NASDAQ:CMND)
Gráfica de Acción Histórica
De May 2023 a May 2024